This is an investigator-initiated, single-arm, prospective clinical study to evaluate the efficacy and safety of heptapopal in the treatment of thrombocytopenia prior to elective surgery
Age ≥18 years old; diagnosis of immune thrombocytopenia.
Platelets ≤75×10^9/L before scheduled elective surgery.
History of allergy to Thrombopoietin Receptor Agonists (TPO-RA) drugs;
Severe bleeding symptoms, such as gastrointestinal bleeding, bleeding of important organs, and intracranial bleeding;
Thrombotic diseases, such as pulmonary embolism, arterial thrombosis and disseminated intravascular coagulation (DIC);
Positive anti-human immunodeficiency virus antibody or anti-treponema pallidum specific antibody;
The Third People's Hospital of Chengdu
Lead sponsor
Affiliated Hospital of North Sichuan Medical College
Collaborator